Read More

Nektar Therapeutics Announces It Will Regain Full Rights To Rezpegaldesleukin, A Novel, First-In-Class Selective Regulatory T-cell Therapy In Clinical Development

Company plans to move REZPEG forward into Phase 2 clinical study in atopic dermatitis SAN FRANCISCO, April 27, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that it will be regaining the full rights to REZPEG from Eli Lilly and Company.

NKTR

Read More

Burgers, Fries, And A $300 Stock Price: The Tantalizing Journey Of McDonald’s To Financial Stardom

McDonald's has introduced flavor-enhancing changes to their popular Big Mac and McDouble burgers and removed artificial preservatives from some food items in their quest for a tastier fast food experience. These enhancements are positively impacting McDonald's appeal to investors, with their shares reaching record highs.

MCD